Authors


Robert H. Hopkins Jr. MD

Latest:

How Should Individuals Interpret the FDA’s Latest COVID-19 Vaccine Authorization?

Robert Hopkins, Jr, MD, medical director of the National Foundation for Infectious Diseases (NFID), discusses what patients are asking about with regards to the vaccines and what the general public should continue to know about their medical value.


Cynthia Miller, MD, MPH

Latest:

The Tripledemic as a Precursor to Stakeholder Alignment under the Quintuple Aim

Infectious disease outbreaks will continue to increase and trying to find strategies to ensure providers are cared for to prevent burnout and shortage staffing is essential if another pandemic arises.



William Cappuccio, PharmD

Latest:

A Plea for New Guidance and Research: Low-Level Viremia in Persons Living With HIV

Current guidelines and primary literature for managing persons living with HIV who have persistently low levels of HIV RNA are scarce. Considering the risks associated with this phenomenon, a call for further guidance and more robust studies are needed for these patients.


Helen Chu, MD, MPH

Latest:

Understanding the Nuances of the RSV Maternal Vaccine and Monoclonal Antibody for the Pediatric Population

With the approval of newer products, clinicians have tools to prevent the respiratory virus in the most vulnerable population. Helen Chu, MD, MPH, offers some insights on their efficacy and the nuances of the delivery of the 2 immunizations.


Olivia G. Funk, PharmD

Latest:

The Next Generation of COVID-19 Vaccines and Boosters

Will there be an answer to keep the continuously evolving virus at bay? Are seasonal combination vaccines the wave of the future?


Dhruv P. Patel, MD

Latest:

Revisiting Old Foes: Updates on HSV

Herpes simplex viruses are chronic infections that underscore racial and ethnic disparities and are afflicting adolescents in increasing numbers.


Matt Weissenbach, DrPH, CPH, CIC, FAPIC

Latest:

Insulating Infection Prevention: How Technology Can Help IP Teams Stay the Course

Infection preventionists face constant regulatory, organizational, and infectious disease challenges, and leveraging evidence-based practices alongside surveillance technology helps them maintain consistency, resilience, and patient safety.


Patricia Seal, MD

Latest:

“Triple Therapy” Facing Triple Threat

Clinicians provide an overview of intraamniotic infections and offer treatment strategies for these challenging infections.


Yosef Nissim PharmD, BCIDP

Latest:

CDC Updates Pneumococcal Conjugate Vaccine Recommendations

The federal agency recommends using either PCV13 or PCV15 as part of a 4-dose series for pediatric patients between the ages of 2-59 months.


Karisma Patel, PharmD, BCPPS, BCIDP

Latest:

Antimicrobial Stewardship: How to Extend a Solid Handshake

In the latest column from SIDP, handshake stewardship prioritizes face-to-face communication between frontline providers to enable feedback to assess the appropriateness of prescribed antimicrobials.


Megan Chatowsky, PharmD Candidate

Latest:

Secnidazole Offers Hope as Option for Treating Trichomoniasis in Women

This nitroimidazole antibiotic is shown to be efficacious for this condition.


Kerry LaPlante, PharmD, FCCP, FIDSA, FIDP

Latest:

Antibiotic Stewardship in Outpatient Care

Although there are challenges for clinical and infectious disease pharmacists when trying to apply this concept, here are some considerations and strategies to employ stewardship in this setting.


Jessa Brenon, PharmD, BCPS, BCIDP

Latest:

Long-Acting Lipoglycopeptides for the Treatment of Severe Infections

Long-acting lipoglycopeptides (LGPs) like dalbavancin, oritavancin, and telavancin were developed with extended half-lives, initially targeting acute bacterial skin and skin structure infections (ABSSSIs). However, recent studies have explored their potential in treating other infections, including infective endocarditis (IE), bone and joint infections (BJIs), and bloodstream infections (BSIs), offering an alternative to standard care and outpatient antimicrobial therapy.


Ian Cook, PharmD, BCACP, AAHIVP, DPLA

Latest:

340B Drug Pricing Program: What Is It and Why Is It Important?

The 340B program has had a great impact on access to HIV treatment and prevention services in the US.


Joseph Glowacki, DO

Latest:

Mixed Fungal Brain Abscess

Clinicians review a patient case including diagnosis, treatment, and follow-up.


Jason M. Broderick

Latest:

MRNA COVID-19 Vaccines and Male Fertility

According to a small study, the Moderna and Pfizer COVID-19 vaccines do not impact male fertility.


Grace McComsey, MD, FIDSA

Latest:

Multidisciplinary Perspectives on HIV Treatment

A multidisciplinary panel concludes a discussion on best practices for managing patients with HIV in various healthcare settings and overcoming social health disparities.


Luise Rogg, MD, PhD

Latest:

ViiV Healthcare Presents Potential Long-Acting HIV Therapies

Phase 1 data on VH184, a third-generation integrase strand transfer inhibitor, and VH499, a novel HIV-1 capsid inhibitor, highlighting their antiviral potency, safety profiles, and potential for long-acting injectable formulations.


Teja Ghanta, PharmD

Latest:

Addressing Neonatal CNS Infections: Case Report of Ceftaroline Therapy in Preterm Infant With Ventriculosubgaleal Shunt

Here is a novel use of ceftaroline to treat methicillin-resistant Staphylococcus epidermidis ventriculitis in a preterm infant with a ventriculosubgaleal shunt.


Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS

Latest:

COVID-19 Booster Shots and the Future

Key opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.


Pelumi Oladipo

Latest:

How Temperature-Sensitive Traits Could Explain Why E coli's Lookalike Goes Undetected

At ASM Microbe 2025, Pelumi Oladipo discusses E marmotae’s reduced motility, misidentification as E coli, and the diagnostic tools closing the gap.



Jeff Fischer, MBA

Latest:

Longhorn Vaccines Develops Sepsis Vaccine Targeting Key Toxins

This composite peptide vaccine targets key bacterial toxins to prevent sepsis, enhance antibiotic efficacy, reduce inflammation in diseases and cancer, with further data expected soon.


Geraldine A. Finlay, MD

Latest:

Identifying Disparities in Sepsis Diagnosis for Unbiased Care

Risk of inaccuracy with pulse oximeters and clinician knowledge gaps in people of color may affect sepsis evaluations and impact treatment plans.



George Loukatos, MD

Latest:

Future Directions for Managing COVID-19 and Influenza

George Loukatos, MD, shares clinical pearls for the management of the SARS-CoV-2 and influenza viruses.


Subramanya Shyam Ganti, MD, MBBS

Latest:

Challenges in the Management of Mycobacterium abscessus Complex

This pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.


Babafemi Taiwo, MBBS

Latest:

Cabotegravir Combined With Broadly Neutralizing Antibodies Maintains Undetectable HIV

In a long-acting dose regimen, an investigational antibodies treatment is a potent antiviral that can function as a component of a complete antiretroviral regimen.


Leilani Valdes, MD, MBA, FCAP

Latest:

How Clinical Labs Help Fight Seasonal Viruses and Address Vaccine Hesitancy

As virus season begins, Leilani Valdes, MD, MBA, FCAP, highlights the lab’s role in early detection and the importance of informed, respectful dialogue on vaccines.

© 2025 MJH Life Sciences

All rights reserved.